Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.


Journal

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 30 07 2019
accepted: 21 10 2019
revised: 17 10 2019
pubmed: 27 11 2019
medline: 20 11 2020
entrez: 27 11 2019
Statut: ppublish

Résumé

To evaluate central macular thickness (CMT), subfoveal choroidal thickness (SFCT), and visual outcomes following different intravitreal anti-vascular endothelial growth factor (VEGF) treatments in eyes with subretinal neovascular membrane (SRNVM) due to type 2 proliferative macular telangiectasia (Mac Tel 2). A total of 38 eyes of 34 patients who underwent intravitreal aflibercept (IVA), intravitreal ranibizumab (IVR), or intravitreal bevacizumab (IVB) injections secondary to SRNVM due to type 2 proliferative MacTel were retrospectively reviewed. The CMT, central macular volume (CMV), best corrected visual acuity (BCVA), and SFCT were evaluated at baseline and at 2 weeks, at 1 month, and at final visits following treatment. Spectral-domain optical coherence tomography and enhanced depth optical coherence tomography were used for the analysis. The mean age of the patients was 58.34 ± 12.48 years (range, 27-79 years). The mean follow-up time was 15.97 ± 6.79 months (range 5-32 months). The mean BCVA showed a statistically significant increase in each group (< 0.001). There was no statistically significant difference in BCVA changes between groups in follow-up periods. There was a significant decrease in CMT following IVA (326.4 ± 168.03 μm to 236 ± 58.33 μm) and IVB (383.71 ± 156.79 μm to 343.85 ± 146.25 μm) (p < 0.001, p = 0.004, respectively) whereas no significant decrease in CMT was observed following IVR (374.57 ± 124.28 μm to 339.71 ± 126.10 μm) (p = 0.65) between baseline and final visit. The SFCT significantly decreased following both IVB and IVR treatments (p = 0.009, p = 0.03, respectively). The IVA, IVR, and IVB were found to be effective with regards to anatomical and visual outcomes in proliferative Mac Tel type 2 patients related with SRNVM. Patients receiving both IVA and IVB needed less injections compared to patients who received IVR. Moreover, IVB and IVR lead to significant decrease in SFCT whereas IVA did not show significant effect on SFCT.

Identifiants

pubmed: 31768680
doi: 10.1007/s00417-019-04520-x
pii: 10.1007/s00417-019-04520-x
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Recombinant Fusion Proteins 0
Vascular Endothelial Growth Factors 0
aflibercept 15C2VL427D
Bevacizumab 2S9ZZM9Q9V
Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1
Ranibizumab ZL1R02VT79

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

99-106

Références

Ophthalmic Res. 2013;49(4):205-8
pubmed: 23364325
Retina. 2012 Nov-Dec;32(10):2001-5
pubmed: 22990322
Arch Ophthalmol. 2006 Apr;124(4):450-60
pubmed: 16606869
Clin Interv Aging. 2009;4:63-5
pubmed: 19503767
Clin Exp Ophthalmol. 2005 Oct;33(5):542-4
pubmed: 16181291
Ophthalmol Ther. 2019 Jun;8(2):155-175
pubmed: 30788805
Ophthalmology. 2007 Sep;114(9):1736-42
pubmed: 17822979
Trends Neurosci. 1996 Aug;19(8):307-12
pubmed: 8843598
Retina. 2004 Jun;24(3):474-8
pubmed: 15187680
Turk J Ophthalmol. 2017 Oct;47(5):279-284
pubmed: 29109897
Eur J Ophthalmol. 2019 Jul;29(4):368-378
pubmed: 30813810
Graefes Arch Clin Exp Ophthalmol. 2008 Aug;246(8):1189-93
pubmed: 18386039
Am J Ophthalmol. 2007 Aug;144(2):296-9
pubmed: 17659962
Am J Ophthalmol. 2011 May;151(5):876-886.e1
pubmed: 21334595
Ophthalmic Surg Lasers Imaging. 2007 Mar-Apr;38(2):164-6
pubmed: 17396701
Arch Ophthalmol. 1982 May;100(5):769-80
pubmed: 7082207
Arch Ophthalmol. 2003 Nov;121(11):1658-9
pubmed: 14609935
Jpn J Ophthalmol. 2010 Jul;54(4):320-4
pubmed: 20700800
Case Rep Ophthalmol Med. 2014;2014:219792
pubmed: 25349755
Eye (Lond). 2010 Sep;24(9):1492-7
pubmed: 20431610
Eye (Lond). 2010 Oct;24(10):1535-41; quiz 1542
pubmed: 20865030
Eur J Ophthalmol. 2006 Sep-Oct;16(5):711-7
pubmed: 17061222
Br J Ophthalmol. 2010 May;94(5):600-5
pubmed: 19846412
Br J Ophthalmol. 1978 Apr;62(4):243-50
pubmed: 565649
Case Rep Ophthalmol. 2012 Sep;3(3):298-303
pubmed: 23275792
Clin Ophthalmol. 2013;7:1357-62
pubmed: 23861579
Ophthalmology. 1993 Oct;100(10):1536-46
pubmed: 8414413
Taiwan J Ophthalmol. 2015 Oct-Dec;5(4):149-155
pubmed: 29018690
Graefes Arch Clin Exp Ophthalmol. 2012 Nov;250(11):1697-9
pubmed: 21863255
Neuroscience. 1993 Jul;55(1):291-301
pubmed: 8350991
Surv Ophthalmol. 2013 Nov-Dec;58(6):536-59
pubmed: 24160729
Retina. 2012 Feb;32 Suppl 1:450-60
pubmed: 22451954
Eur J Ophthalmol. 2008 Jul-Aug;18(4):587-90
pubmed: 18609479
Retina. 1999;19(4):332-5
pubmed: 10458300
Arch Ophthalmol. 2003 Sep;121(9):1345-6
pubmed: 12963631
Eye (Lond). 2011 Dec;25(12):1663-5; author reply 1665
pubmed: 21997355
Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1825-9
pubmed: 17345090
Br J Ophthalmol. 2008 Jul;92(7):941-5
pubmed: 18577646
Retina. 2012 May;32(5):996-1006
pubmed: 22266930
Case Rep Med. 2014;2014:786578
pubmed: 24876845

Auteurs

Buğra Karasu (B)

Department of Ophthalmology, University of Health Sciences, Beyoglu Eye Training and Research Hospital, Bereketzade Mah, Bereketzade Sok. No: 2, Beyoğlu, 34421, Istanbul, Turkey. bugra_karasu@hotmail.com.

Betul Onal Gunay (BO)

Department of Ophthalmology, University of Health Sciences, Trabzon Kanuni Training and Research Hospital, Trabzon, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH